Trial Profile
Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 10 Sep 2019 Results published in the Investigational New Drugs
- 11 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.